Published in Cancer Res on July 01, 1972
Antiviral activity and induction of interferon-like substance by quinacrine and acranil. Antimicrob Agents Chemother (1973) 1.09
Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone. Clin Exp Immunol (1978) 0.88
Mechanism of cellular suppression induced by oral tilorone treatment of mice. Infect Immun (1980) 0.81
Effect of tilorone on susceptibility of mice to primary or secondary infection with Listeria monocytogenes. Infect Immun (1976) 0.79
Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours. Clin Exp Immunol (1996) 0.76
Depletion of lymphoid tissues by tilorone. Ultrastructure and synergistic interaction with antilymphocyte serum. Am J Pathol (1983) 0.75
Inhibition of herpesvirus deoxyribonucleic acid and protein synthesis by tilorone hydrochloride. Antimicrob Agents Chemother (1976) 0.75
Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol (1995) 3.45
Hemangioendothelial sarcoma of liver from chronic arsenic intoxication by Fowler's solution. Cancer (1968) 2.22
Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer (1981) 2.05
Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests. Fundam Appl Toxicol (1992) 1.83
Development of a testing battery to assess chemical-induced immunotoxicity: National Toxicology Program's guidelines for immunotoxicity evaluation in mice. Fundam Appl Toxicol (1988) 1.71
Subchronic 10 day immunotoxicity of polydimethylsiloxane (silicone) fluid, gel and elastomer and polyurethane disks in female B6C3F1 mice. Drug Chem Toxicol (1994) 1.23
Induction of macrophage-mediated tumor-cell cytotoxicity by pyran copolymer. J Natl Cancer Inst (1974) 1.23
Have we found the "definitive cancer biomarker"? The diagnostic and therapeutic implications of human chorionic gonadotropin-beta expression as a key to malignancy. Cancer (1995) 1.22
Interferon induction in man by a synthetic polyanion of defined composition. N Engl J Med (1967) 1.19
Stimulation of antibody formation by pyran copolymer. Proc Soc Exp Biol Med (1970) 1.15
Antineoplastic activity of cannabinoids. J Natl Cancer Inst (1975) 1.14
New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res (1979) 1.13
The weakening of the Oslerian tradition. The changing emphasis in departments of medicine. JAMA (1978) 1.13
Antibacterial and immunostimulating casein-derived substances from milk: casecidin, isracidin peptides. Food Chem Toxicol (1996) 1.12
Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol (1988) 1.10
Anti-glucocorticoid effects of dehydroepiandrosterone (DHEA). Mol Cell Biochem (1994) 1.08
Comparison of ELISA and plaque-forming cell assays for measuring the humoral immune response to SRBC in rats and mice treated with benzo[a]pyrene or cyclophosphamide. Fundam Appl Toxicol (1993) 1.07
Chemotherapy as an adjuvant to surgery for colorectal cancer. Ann Surg (1975) 1.07
Molecular regulation of IL-6 activation by asbestos in lung epithelial cells: role of reactive oxygen species. J Immunol (1997) 1.06
Comparison of mouse strains using the local lymph node assay. Toxicology (2000) 1.05
Norepinephrine and the antibody response. Pharmacol Rev (1985) 1.03
Toxicology of chloral hydrate in the mouse. Environ Health Perspect (1982) 1.02
Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol (1993) 1.00
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity. J Med Chem (1979) 1.00
Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents. Adv Enzyme Regul (1980) 1.00
Pineal control of aging: effect of melatonin and pineal grafting on aging mice. Proc Natl Acad Sci U S A (1994) 0.99
Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infect Immun (1979) 0.99
Biphasic response of the reticuloendothelial system (RES) induced by pyran copolymer. J Reticuloendothel Soc (1970) 0.98
Immunotoxicity of the semiconductor gallium arsenide in female B6C3F1 mice. Fundam Appl Toxicol (1989) 0.96
Antiviral activity and side effects of polyriboinosinic-cytidylic acid complexes as affected by molecular size. Proc Natl Acad Sci U S A (1972) 0.93
Humoral and cell-mediated immune status in mice exposed to chloral hydrate. Environ Health Perspect (1982) 0.92
The pineal control of aging. The effects of melatonin and pineal grafting on the survival of older mice. Ann N Y Acad Sci (1991) 0.92
Review of the application of response surface methodology in the combination therapy of cancer. Cancer Treat Rep (1986) 0.91
Qualitative and quantitative experimental models to aid in risk assessment for immunotoxicology. Toxicol Lett (1992) 0.90
Chromatin and histones in mealy bug cell explants: activation and decondensation of facultative heterochromatin by a synthetic polyanion. Chromosoma (1971) 0.90
Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proc Soc Exp Biol Med (1999) 0.90
Molecular mechanism of RU 486 action: a review. Mol Cell Biochem (1992) 0.90
Pyran and polyribonucleotides: differences in biological activities. Antimicrob Agents Chemother (1972) 0.89
Role of sensitization routes in the development of type I hypersensitivity to natural rubber latex in mice. Am J Ind Med (1999) 0.89
An immunotoxicological evaluation of 4,4'-thiobis-(6-t-butyl-m-cresol) in female B6C3F1 mice. 2. Humoral and cell-mediated immunity, macrophage function, and host resistance. Fundam Appl Toxicol (1988) 0.88
Tissue localization studies in evaluating the functional role of the RES. J Reticuloendothel Soc (1970) 0.88
Chloramphenicol-associated encephalopathy. Clin Pharmacol Ther (1970) 0.88
Norepinephrine and serotonin content of the murine spleen: its relationship to lymphocyte beta-adrenergic receptor density and the humoral immune response in vivo and in vitro. Cell Immunol (1988) 0.87
Effect of bacterial lipopolysaccharide, lipid A, and concanavalin A on lethality of 5-fluorouracil for mice. Toxicol Appl Pharmacol (1975) 0.87
The effects of maleic anhydride-divinyl ether (MVE) copolymers on hepatic microsomal mixed-function oxidases and other biologic activities. J Pharmacol Exp Ther (1979) 0.87
The antimitotic activity of polyanions (antitumor, antiviral, and antibacterial action of heparin, heparinoids, anionic dyes, and synthetic polymers). Adv Chemother (1968) 0.86
Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer (1977) 0.86
Evidence for arsenic as the immunosuppressive component of gallium arsenide. Toxicol Appl Pharmacol (1991) 0.86
Correlation of suppressed natural killer cell activity with altered host resistance models in B6C3F1 mice. Toxicol Appl Pharmacol (2001) 0.86
Effect of delta 9-tetrahydrocannabinol on herpes simplex virus type 2 vaginal infection in the guinea pig. Proc Soc Exp Biol Med (1986) 0.85
Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy. Cancer Treat Rep (1978) 0.85
The effect of stimulants and depressants of reticuloendothelial activity on drug metabolism. J Reticuloendothel Soc (1971) 0.85
Immunotoxic effects of diethylstilbestrol on host resistance: comparison with cyclophosphamide. J Leukoc Biol (1984) 0.84
In vitro immunotoxicological assays for detection of compounds requiring metabolic activation. Environ Health Perspect (1982) 0.84
Beta adrenoceptor mediation of the enhancing effect of norepinephrine on the murine primary antibody response in vitro. J Pharmacol Exp Ther (1984) 0.84
Estimation of the median lethal dose when responses within a little are correlated. Biometrics (1981) 0.83
Enhanced susceptibility of mice to combinations of delta 9-tetrahydrocannabinol and live or killed gram-negative bacteria. Infect Immun (1977) 0.83
Glucocorticoids enhance the potency of Schwann cell mitogens. J Neurosci Res (1994) 0.83
Immunological responses of mice following administration of natural rubber latex proteins by different routes of exposure. Toxicol Sci (2000) 0.83
Splenic cell targets in gallium arsenide-induced suppression of the primary antibody response. Toxicol Appl Pharmacol (1991) 0.83
A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: in vitro toxicity to precursor cells and microstromal environment. Toxicol Appl Pharmacol (1989) 0.83
The growth-regulating activity of polyanions: a theoretical discussion of their place in the intercellular environment and their role in cell physiology. Adv Cancer Res (1968) 0.82
In vitro inhibition of the primary antibody response to sheep erythrocytes by cyclophosphamide. Toxicol Appl Pharmacol (1981) 0.82
Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. Toxicol Appl Pharmacol (2000) 0.82
Humoral and cell-mediated immune status of mice exposed to trans-1,2-dichloroethylene. Drug Chem Toxicol (1985) 0.82
Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. J Clin Oncol (1995) 0.81
Antitumor activity and toxicity of peroxo heteroligand vanadates(V) in relation to biochemistry of vanadium. J Inorg Biochem (1985) 0.81
Antitumor activity of homo-aza-steroidal esters of [p-[bis(2-chloroethyl)amino]phenyl]acetic acid and [p-[bis(2-chloroethyl)amino]phenyl]butyric acid. Cancer Chemother Pharmacol (1983) 0.81
Combination chemotherapy: arriving at optimal treatment levels by incorporating side effect constraints. Cancer Treat Rep (1978) 0.81
Suppression of splenic accessory cell function in mice exposed to gallium arsenide. Toxicol Appl Pharmacol (1991) 0.81
Glycidol modulation of the immune responses in female B6C3F1 mice. Drug Chem Toxicol (2000) 0.81
The toxicity of some halomethanes in mice. Toxicol Appl Pharmacol (1978) 0.81
Structure-activity relationships of natural and synthetic cannabinoids in suppression of humoral and cell-mediated immunity. J Pharmacol Exp Ther (1978) 0.81
Humoral and cell-mediated immune status in mice exposed to trichloroethylene in the drinking water. Toxicol Appl Pharmacol (1982) 0.81
Gallium arsenide selectively inhibits T cell proliferation and alters expression of CD25 (IL-2R/p55). J Pharmacol Exp Ther (1993) 0.81
Effects of hydroxyethylstarch (Hespan), a plasma expander, on the functional activity of the reticuloendothelial system. Comparison with human serum albumin and pyran copolymer. Drug Chem Toxicol (1986) 0.81
Effects of delta9-tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J Natl Cancer Inst (1976) 0.81
Drug activity and therapeutic synergism in cancer treatment. Cancer Res (1982) 0.81
In vivo assessment of immunotoxicity. Environ Health Perspect (1982) 0.81
Immunotherapy with autologous white cell infusions ("lymphocytes") in the treatment of recurrrent glioblastoma multiforme: a preliminary report. Cancer (1977) 0.81
Longitudinal assessment of the low-end specificity of maternal reports of depressive symptoms. Behav Res Ther (1999) 0.80
Future direction of synthetic polyanions (pyran copolymer). Cancer Treat Rep (1978) 0.80
Reversal of gallium arsenide-induced suppression of the antibody response by a mixed disulfide metabolite of meso-2,3-dimercaptosuccinic acid. J Pharmacol Exp Ther (1993) 0.80
Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma. Cancer (1979) 0.80
The B lymphocyte is the immune cell target for 2',3'-dideoxyadenosine. Toxicol Appl Pharmacol (1990) 0.80
Enhanced cytotoxicity in mice of combinations of concanavalin A and selected antitumor drugs. Adv Exp Med Biol (1975) 0.80
Relationship of molecular weight to antiviral and antitumor activities and toxic effects of maleic anhydride-divinyl ether (MVE) polyanions. Cancer Treat Rep (1978) 0.80
Experimental studies of the hematologic and immune system toxicity of nucleoside derivatives used against HIV infection. Int J Immunopharmacol (1991) 0.80
Lethal interaction of bacterial lipopolysaccharide and naturally occurring cannabinoids. J Reticuloendothel Soc (1978) 0.80
On determining the levels of treatment to optimize the probability of a favorable response. Cancer Treat Rep (1977) 0.80
Enhanced toxicity for mice of combinations of bacterial lipopolysaccharide and vincristine. Antimicrob Agents Chemother (1976) 0.80
Survival analysis of drug combinations using a hazards model with time-dependent covariates. Biometrics (1980) 0.80
Immunotoxicological profile of morphine sulfate in B6C3F1 female mice. Fundam Appl Toxicol (1994) 0.80